Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study
- 4 June 2021
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 30 (9) , 1459-1468
Abstract
Objective: Osteonecrosis (ON), which can lead to physical disability, is a common complication of systemic lupus erythematosus (SLE). The purpose of this study was to determine the prevalence of ON and identify possible risk factors in Chinese SLE patients. Methods: SLE patients who fulfilled the 1997 American College of Rheumatology SLE classification criteria were recruited from the Peking Union Medical College Hospital. The chi-square test (χ 2 test) and multivariate regression analyses were used to evaluate risk factors. The Cox proportional-hazards model was used to construct the survival curves and estimate the simultaneous effects of prognostic factors on survival. Results: We consecutively enrolled 1,158 patients, of which 88 patients (7.6%) developed ON. Among ON patients, 57.1% of patients had isolated femoral head necrosis and 42.9% had multiple joint involvement. The mean age of ON patients (24.62 ± 8.89 years) was significantly younger than SLE patients without ON (27.23 ± 10.16 years, p = 0.09). The ON group presented with a much longer disease course (10.68 ± 5.97 years, p < 0.001) and increased incidence of arthritis, kidney, and central nervous system (CNS) involvement (65.9% [ p < 0.05], 57.6% [ p < 0.05], and 16.5% [ p < 0.05], respectively, in the ON group). ON patients were more likely to be treated with glucocorticoid (GC) and to receive a high dose of prednisolone at the initial stage of SLE ( p < 0.05). The percentage of patients who received hydroxychloroquine was much higher in the control group ( p < 0.001). Cox regression analysis suggested that CNS involvement and GC therapy were two independent risk factors for ON in SLE patients. The presence of anti-phospholipid antibodies (aPLs) was a risk factor for multiple joint necrosis (odds ratio: 6.28, p = 0.009). Conclusions: ON remains a serious and irreversible complication in SLE. In addition to glucocorticoid therapy, we found that CNS system involvement was a risk factor for ON, while the administration of hydroxychloroquine was a protective factor. The clinical characteristics of multiple site ON patients were distinct from isolated femoral head necrosis patients. The presence of aPLs was a risk factor for multiple site osteonecrosis.Keywords
Funding Information
- CAMS Innovation Fund for Medical Sciences (2019-I2M-2-008)
- The Chinese National Key Technology R&D Program, Ministry of Science and Technology (2017YFC0907601, 2017YFC0907602, 2017YFC0907603)
- Beijing Municipal Science & Technology Commission (No. Z 201100005520022,23, 25-27)
This publication has 42 references indexed in Scilit:
- Factors Associated With Osteonecrosis in Thai Lupus PatientsJCR: Journal of Clinical Rheumatology, 2009
- Multifocal avascular necrosis revealing antiphospholipid syndromeClinical Rheumatology, 2007
- Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control studyAnnals of the Rheumatic Diseases, 2006
- Does Alendronate Prevent Collapse in Osteonecrosis of the Femoral Head?Clinical Orthopaedics and Related Research, 2006
- Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label studyRheumatology, 2005
- Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatmentAnnals of the Rheumatic Diseases, 2001
- A vascular Osteonecrosis in Patients with SLE: Relation to Corticosteroid Therapy and Anticardiolipin AntibodiesLupus, 1994
- The “Primary” Antiphospholipid SyndromeMedicine, 1989
- Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities.Annals of the Rheumatic Diseases, 1989
- ISCHEMIC NECROSIS OF BONE IN SYSTEMIC LUPUS ERYTHEMATOSUSMedicine, 1976